Jessica Skarzynski | Authors

February 12, 2021

Darolutamide still has a favorable safety profile with prolonged treatment among patients with nonmetastatic castration-resistant prostate cancer.

January 30, 2021

Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.

January 16, 2021

Three abstracts reported at a medical meeting indicate that the combination of pembrolizumab plus lenvatinib is active in various gastrointestinal cancers.

December 10, 2020

Treatment with the combination of oral paclitaxel and encequidar was found to be associated with greater efficacy in patients with metastatic breast cancer, as well as lower rates of chemotherapy-induced peripheral neuropathy, compared to intravenous paclitaxel.

December 05, 2020

The telomerase inhibitor demonstrated improved overall survival spleen response, and symptom response in patients with myelofibrosis.

May 29, 2020

Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma.

May 28, 2020

Chemotherapy use in patients with lung and other thoracic cancers who are also diagnosed with COVID-19 was found to be associated with an increased risk of death compared to other treatment methods.